Program
QLS7305
A development code. Also written as “QLS7305 Injection”.
Its studies are mostly in Glomerulonephritis, IGA, led by Qilu Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Qilu Pharmaceutical | 22 open or running | phase 2since Jul 17, 2026 | Nov 14, 2025 | Dec 2027phase 1 · NCT07313150 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 14, 2025First study: phase 1 study in Healthy Volunteers - Male and FemaleFirst studyNCT07313150 · 60 planned
- Jul 17, 2026Phase 2 study in Glomerulonephritis, IGAPhase 2 reachedNCT07730632 · 60 planned · China
Ahead
- Dec 2027Primary completion: phase 1 study in Healthy Volunteers - Male and FemaleNCT07313150
- Aug 10, 2028Primary completion: phase 2 study in Glomerulonephritis, IGANCT07730632
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07730632Glomerulonephritis, IGA · China | 2 | Not yet recruiting | Aug 10, 2028 | 60 |
| NCT07313150Healthy Volunteers - Male and Female | 1 | Not yet recruiting | Dec 2027 | 60 |
How it is read
Names in the registry
- “QLS7305 Injection”, 2 entries
Codes read as this program: QLS7305.
Conditions, from the studies’ own filings
- Glomerulonephritis, IGA, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.